In December 2025, EVP of Access & Pricing Tim Wright presented the first of a series of exclusive updates on Most-Favored-Nation pricing, developed in partnership with The Evidence Base. Please note that a more up-to-date episode of this series is now available. To watch this and to secure exclusive access to the latest video updates as they happen, please register your interest via the link above.

Most-favored-nation (MFN) pricing proposes linking US drug prices to those paid in selected international reference markets, creating significant uncertainty for manufacturers as policymakers consider multiple implementation pathways.

As most-favoured-nation pricing policy continues to evolve, we remain committed to informing our connections and clients of every significant development. Throughout 2026 and in collaboration with The Evidence Base, Tim will be sharing regular strategic updates and video commentary on MFN pricing.

Please contact us if you have questions or would like a copy of the slides. Register for future MFN updates.

Explore our Access & Pricing Solutions

About the presenter

Tim Wright leads the Access & Pricing division at Genesis Research Group. An economist and health economist, Tim has 30 years of experience in the biopharma sector, including 18 years in executive positions in strategic consulting firms and 12 years in global EU and UK roles in industry. In consulting, Tim has provided strategic leadership in over 1000 engagements with small biotechs to top-five pharma and across all therapy areas. Within the industry, Tim was responsible for global pricing and access strategy for two mega-brands and the CV, respiratory, infection and inflammation early asset portfolio at AstraZeneca. He is former Head of HEOR at Janssen Cilag UK, and brings experience from EU Pricing for Allergan and his time as a clinical scientist at Astra.